22.55
Celldex Therapeutics Inc stock is traded at $22.55, with a volume of 166.85K.
It is down -0.67% in the last 24 hours and down -5.18% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
See More
Previous Close:
$22.70
Open:
$22.71
24h Volume:
166.85K
Relative Volume:
0.19
Market Cap:
$1.51B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-8.7403
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+2.91%
1M Performance:
-5.18%
6M Performance:
-34.03%
1Y Performance:
-41.05%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CLDX
Celldex Therapeutics Inc
|
22.55 | 1.51B | 9.98M | -154.08M | -159.66M | -2.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.06 | 117.87B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
678.97 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
643.04 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
249.82 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
121.07 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-13-25 | Initiated | UBS | Buy |
Oct-07-24 | Initiated | Citigroup | Buy |
Sep-30-24 | Initiated | Goldman | Neutral |
Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jun-18-24 | Initiated | Stifel | Buy |
Jun-11-24 | Initiated | Wolfe Research | Outperform |
Dec-20-23 | Initiated | TD Cowen | Outperform |
Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Aug-22-23 | Initiated | Wells Fargo | Underweight |
Sep-17-21 | Initiated | Jefferies | Buy |
Sep-10-21 | Initiated | SVB Leerink | Outperform |
Jul-22-21 | Initiated | Guggenheim | Buy |
Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-07-16 | Initiated | Aegis Capital | Buy |
Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
Mar-01-16 | Initiated | H.C. Wainwright | Buy |
Aug-11-15 | Reiterated | Brean Capital | Buy |
Aug-11-15 | Reiterated | Oppenheimer | Outperform |
Aug-11-15 | Reiterated | ROTH Capital | Buy |
Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
Nov-17-14 | Reiterated | ROTH Capital | Buy |
Mar-04-14 | Reiterated | Oppenheimer | Outperform |
Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Feb-26-13 | Reiterated | Oppenheimer | Outperform |
Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
Oct-02-12 | Reiterated | Oppenheimer | Outperform |
Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
TSP Capital Management Group LLC Lowers Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from Analysts at UBS Group - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Brokers Issue Forecasts for CLDX Q1 Earnings - MarketBeat
Sovran Advisors LLC Acquires New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
UBS Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN
Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $20.99 amid market challenges - MSN
CLDXU.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH - br.ADVFN.com
FY2025 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? - Seeking Alpha
CLDX’s latest rating updates from top analysts. - Knox Daily
What is Leerink Partnrs' Estimate for CLDX FY2028 Earnings? - MarketBeat
It is Poised to be a Bull Market for Celldex Therapeutics Inc (CLDX) - SETE News
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Celldex Therapeutics Inc (CLDX)’s stock performance: a year in review - US Post News
Investing in Celldex Therapeutics Inc (CLDX): What You Must Know - Knox Daily
Checking in on Checkpoint Therapeutics Inc (CKPT) after recent insiders movement - Knox Daily
Stephens initates Catalyst Pharmaceuticals Inc (CPRX) stock to an Overweight - Knox Daily
Celldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Australia
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts CLDX FY2025 Earnings - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa
Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Option Exercise |
10.16 |
20,169 |
204,990 |
45,297 |
Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Sale |
35.42 |
17,172 |
608,315 |
28,125 |
Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Option Exercise |
10.38 |
30,000 |
311,400 |
39,074 |
Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Sale |
34.87 |
30,000 |
1,045,962 |
9,074 |
Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 11 '24 |
Option Exercise |
2.71 |
15,000 |
40,650 |
17,115 |
Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Option Exercise |
9.70 |
15,000 |
145,474 |
24,074 |
Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Sale |
35.06 |
15,000 |
525,873 |
9,074 |
Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 07 '24 |
Sale |
35.26 |
45,000 |
1,586,844 |
2,115 |
Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Jun 05 '24 |
Option Exercise |
10.38 |
9,540 |
99,025 |
35,464 |
Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS |
Jun 03 '24 |
Option Exercise |
10.25 |
64,658 |
662,575 |
71,752 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):